CCM
CHRS icon

Camber Capital Management’s Coherus Oncology CHRS Stock Holding History

Camber Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,200,000
Closed -$38.2M – 38
2020
Q4 		$38.2M Hold
2,200,000
– – 1.34% 25
2020
Q3 		$40.3M Hold
2,200,000
– – 2.13% 19
2020
Q2 		$39.3M Buy
+2,200,000
New +$37.2M 2.25% 15

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Camber Capital Management's CHRS Position: Q1 2021 in Review

Camber Capital Management sold out of Coherus Oncology (CHRS) in Q1 2021, closing a stake of 2,200,000 shares — an estimated $38.2M sold.

Camber Capital Management first reported a position in CHRS in Q2 2020 and held it in 3 quarters. The position peaked at $40.3M in Q3 2020. 205 funds tracked by Wall St. Rank hold CHRS as of Q1 2021.

  • Camber Capital Management reported no remaining Coherus Oncology position as of Q1 2021 after selling out during the quarter.
  • Camber Capital Management sold 2,200,000 Coherus Oncology shares in Q1 2021, an estimated $38.2M.
  • Camber Capital Management first reported a position in Coherus Oncology in Q2 2020 and held it in 3 quarters.
  • Camber Capital Management's Coherus Oncology position peaked at $40.3M in Q3 2020.
  • 205 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2021.

Based on Camber Capital Management's 13F filing for Q1 2021, filed 17 May 2021.